Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2.

Duncton MA, Piatnitski Chekler EL, Katoch-Rouse R, Sherman D, Wong WC, Smith LM 2nd, Kawakami JK, Kiselyov AS, Milligan DL, Balagtas C, Hadari YR, Wang Y, Patel SN, Rolster RL, Tonra JR, Surguladze D, Mitelman S, Kussie P, Bohlen P, Doody JF.

Bioorg Med Chem. 2009 Jan 15;17(2):731-40. doi: 10.1016/j.bmc.2008.11.049. Epub 2008 Nov 24.

PMID:
19101155
2.

Synthesis and evaluation of heteroaryl-ketone derivatives as a novel class of VEGFR-2 inhibitors.

Piatnitski Chekler EL, Katoch-Rouse R, Kiselyov AS, Sherman D, Ouyang X, Kim K, Wang Y, Hadari YR, Doody JF.

Bioorg Med Chem Lett. 2008 Aug 1;18(15):4344-7. doi: 10.1016/j.bmcl.2008.06.083. Epub 2008 Jun 28.

PMID:
18640036
3.

Targeted therapy of the insulin-like growth factor-1 receptor in cancer.

Paz K, Hadari YR.

Comb Chem High Throughput Screen. 2008 Jan;11(1):62-9. Review.

PMID:
18220543
4.

Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers.

Doody JF, Wang Y, Patel SN, Joynes C, Lee SP, Gerlak J, Rolser RL, Li Y, Steiner P, Bassi R, Hicklin DJ, Hadari YR.

Mol Cancer Ther. 2007 Oct;6(10):2642-51. Epub 2007 Oct 3.

5.

Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.

Steiner P, Joynes C, Bassi R, Wang S, Tonra JR, Hadari YR, Hicklin DJ.

Clin Cancer Res. 2007 Mar 1;13(5):1540-51.

6.

Novel tricyclic azepine derivatives: Biological evaluation of pyrimido[4,5-b]-1,4-benzoxazepines, thiazepines, and diazepines as inhibitors of the epidermal growth factor receptor tyrosine kinase.

Smith L 2nd, Wong WC, Kiselyov AS, Burdzovic-Wizemann S, Mao Y, Xu Y, Duncton MA, Kim K, Piatnitski EL, Doody JF, Wang Y, Rosler RL, Milligan D, Columbus J, Balagtas C, Lee SP, Konovalov A, Hadari YR.

Bioorg Med Chem Lett. 2006 Oct 1;16(19):5102-6. Epub 2006 Aug 2.

PMID:
16887347
7.

Tricyclic azepine derivatives: pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors.

Smith L 2nd, Piatnitski EL, Kiselyov AS, Ouyang X, Chen X, Burdzovic-Wizemann S, Xu Y, Pan W, Chen X, Wang Y, Rosler RL, Patel SN, Chiang HH, Milligan DL, Columbus J, Wong WC, Doody JF, Hadari YR.

Bioorg Med Chem Lett. 2006 Mar 15;16(6):1643-6. Epub 2006 Jan 18. Erratum in: Bioorg Med Chem Lett. 2006 Jul 15;16(14):3869. Pan, Weitao [added]; Chen, Xin [added].

PMID:
16412636
8.

Human single-domain neutralizing intrabodies directed against Etk kinase: a novel approach to impair cellular transformation.

Paz K, Brennan LA, Iacolina M, Doody J, Hadari YR, Zhu Z.

Mol Cancer Ther. 2005 Nov;4(11):1801-9.

9.

Pyrimido-oxazepine as a versatile template for the development of inhibitors of specific kinases.

Pan W, Liu H, Xu YJ, Chen X, Kim KH, Milligan DL, Columbus J, Hadari YR, Kussie P, Wong WC, Labelle M.

Bioorg Med Chem Lett. 2005 Dec 15;15(24):5474-7. Epub 2005 Sep 28.

PMID:
16198560
10.

Protein kinases in drug discovery and development.

Hadari YR.

IDrugs. 2001 Dec;4(12):1329-32.

PMID:
15931557
11.

Role of galectin-8 as a modulator of cell adhesion and cell growth.

Zick Y, Eisenstein M, Goren RA, Hadari YR, Levy Y, Ronen D.

Glycoconj J. 2002;19(7-9):517-26. Review.

PMID:
14758075
12.

Immunohistochemical profile of galectin-8 expression in benign and malignant tumors of epithelial, mesenchymatous and adipous origins, and of the nervous system.

Danguy A, Rorive S, Decaestecker C, Bronckart Y, Kaltner H, Hadari YR, Goren R, Zich Y, Petein M, Salmon I, Gabius HJ, Kiss R.

Histol Histopathol. 2001 Jul;16(3):861-8. doi: 10.14670/HH-16.861.

PMID:
11510978
13.

Critical role for the docking-protein FRS2 alpha in FGF receptor-mediated signal transduction pathways.

Hadari YR, Gotoh N, Kouhara H, Lax I, Schlessinger J.

Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8578-83. Epub 2001 Jul 10.

14.

Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.

Melillo RM, Santoro M, Ong SH, Billaud M, Fusco A, Hadari YR, Schlessinger J, Lax I.

Mol Cell Biol. 2001 Jul;21(13):4177-87.

15.

Galectin-8 functions as a matricellular modulator of cell adhesion.

Levy Y, Arbel-Goren R, Hadari YR, Eshhar S, Ronen D, Elhanany E, Geiger B, Zick Y.

J Biol Chem. 2001 Aug 17;276(33):31285-95. Epub 2001 May 22.

16.

Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins.

Ong SH, Hadari YR, Gotoh N, Guy GR, Schlessinger J, Lax I.

Proc Natl Acad Sci U S A. 2001 May 22;98(11):6074-9. Epub 2001 May 15.

17.

Galectin-8 binding to integrins inhibits cell adhesion and induces apoptosis.

Hadari YR, Arbel-Goren R, Levy Y, Amsterdam A, Alon R, Zakut R, Zick Y.

J Cell Sci. 2000 Jul;113 ( Pt 13):2385-97.

18.
19.
20.

A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway.

Kouhara H, Hadari YR, Spivak-Kroizman T, Schilling J, Bar-Sagi D, Lax I, Schlessinger J.

Cell. 1997 May 30;89(5):693-702.

21.
22.

Interaction between the insulin receptor and its downstream effectors. Use of individually expressed receptor domains for structure/function analysis.

Paz K, Voliovitch H, Hadari YR, Roberts CT Jr, LeRoith D, Zick Y.

J Biol Chem. 1996 Mar 22;271(12):6998-7003.

23.

Tyrosine phosphorylation of insulin receptor substrate-1 in vivo depends upon the presence of its pleckstrin homology region.

Voliovitch H, Schindler DG, Hadari YR, Taylor SI, Accili D, Zick Y.

J Biol Chem. 1995 Jul 28;270(30):18083-7.

24.

Galectin-8. A new rat lectin, related to galectin-4.

Hadari YR, Paz K, Dekel R, Mestrovic T, Accili D, Zick Y.

J Biol Chem. 1995 Feb 17;270(7):3447-53.

25.

Modulation of protein tyrosine phosphorylation in rat insular cortex after conditioned taste aversion training.

Rosenblum K, Schul R, Meiri N, Hadari YR, Zick Y, Dudai Y.

Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1157-61.

26.
27.

Insulin and insulinomimetic agents induce activation of phosphatidylinositol 3'-kinase upon its association with pp185 (IRS-1) in intact rat livers.

Hadari YR, Tzahar E, Nadiv O, Rothenberg P, Roberts CT Jr, LeRoith D, Yarden Y, Zick Y.

J Biol Chem. 1992 Sep 5;267(25):17483-6. Erratum in: J Biol Chem 1993 Apr 25;268(12):9156.

28.

pH-dependent pore formation properties of pardaxin analogues.

Shai Y, Hadari YR, Finkels A.

J Biol Chem. 1991 Nov 25;266(33):22346-54.

Supplemental Content

Loading ...
Support Center